Companies ›Healthcare ›AIMD.O

AIMD.O — NASDAQ Pharmaceuticals & Medical Research

Ainos Inc

$1,38

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

10,0M USD

P/E

—

EV / Rev

—

Div yield

—

Op margin

-11 268,0 %

ROE

-195,3 %

Net margin

-11 896,8 %

Debt / equity

1,45

Beta

—

52w range

—

Volume

744

Day range

—

Prev close

$3,16

Open

—

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

Ainos Inc is a biotechnology and medical research company focused on pharmaceuticals and medical research.

Business. Ainos Inc (AIMD.O) is a biotechnology and medical research company headquartered in the United States. The firm operates within the pharmaceuticals and medical research sector, focusing on product-based revenue models typical of the industry. It is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available.

Classification99 %

SectorHealth Care

Industry groupPharmaceuticals & Medical Research

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

EarningsQ3 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership→

Geode Capital Management, L.L.C.

largest disclosed fund holder

Profitability→

-195,3 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning AIMD.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to AIMD.O. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Ainos Inc (AIMD.O) is a biotechnology and medical research company headquartered in the United States. The firm operates within the pharmaceuticals and medical research sector, focusing on product-based revenue models typical of the industry. It is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available.

Classification99 %

SectorHealth Care

Industry groupPharmaceuticals & Medical Research

AI synthesis

GENERATED

Ainos Inc has a market capitalization of $12.72 million and a price-to-book ratio of 1.68, indicating that the market values the company at a premium to its book value. The company's liquidity position is characterized by a current ratio of 1.06, suggesting limited short-term liquidity cushion. With only $417,350 in cash and equivalents and $11 million in long-term debt, the company's net cash position is negative, raising concerns about its ability to meet long-term obligations without additional financing.

Profitability metrics reveal significant challenges for Ainos Inc. The company reported a net loss of $14.77 million and an operating loss of $13.99 million in the latest period. Return on equity (ROE) is -195.32%, and return on assets (ROA) is -7.08%, both far below industry norms. The gross profit margin of 82.9% is strong, but this is insufficient to offset the company's high operating expenses.

Geographic and segment exposure data is not available in the provided dataset, but the company's revenue concentration appears to be limited to a single business line given the absence of disclosed segments. This lack of diversification increases vulnerability to sector-specific risks.

Growth prospects are constrained by the company's financial performance. Revenue of $124.16 million in the latest period is offset by a net loss of $14.77 million. The company's free cash flow is negative at -$10.04 million, and capital expenditures of -$34,560 suggest minimal investment in growth infrastructure. Analysts have recorded a last actual revenue of $134 million, indicating some level of revenue stability despite the net loss.

The company's risk profile is elevated by its negative net cash position and high debt-to-equity ratio of 1.45. While dilution risk is currently assessed as low, the company's operating cash flow of -$4.61 million and free cash flow of -$10.04 million suggest potential future financing needs that could lead to share dilution. No recent events or filings are disclosed in the provided dataset, but the company's financial performance and liquidity position warrant close monitoring.

Key takeaways

Ainos Inc has a negative net income of $14.77 million and a negative return on equity of -195.32%.
The company's liquidity position is weak, with a current ratio of 1.06 and negative net cash after subtracting total debt.
Despite a strong gross profit margin of 82.9%, the company's operating and net losses indicate significant cost overruns.
The company's market capitalization of $12.72 million is significantly lower than its enterprise value to revenue multiple of 187.65.
Ainos Inc has a high debt-to-equity ratio of 1.45, indicating a leveraged capital structure.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation

Market price

$1,38

Market cap

$12.7M

Enterprise valueⓘ

$23.3M

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

1.7x

P / Tangible bookⓘ

1.7x

Tangible book

$7.6M

Net cashⓘ

-$10.6M

Current ratioⓘ

1.1

Debt / equityⓘ

1.4

ROAⓘ

-70.8%

ROEⓘ

-2.0%

Cash conversionⓘ

31.0%

CapEx / revenueⓘ

-27.8%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

Business relationships5 disclosed relationships · 3 types · extracted from filings & disclosures

Customers1

ANON:CUST:AIMD.O:CustomerAANON:CUST:AIMD.O:CustomerACustomer88%Source ↗

Partners3

Solomon Technology Corp2359.TWPartner90%Source ↗

Topco Scientific Co Ltd5434.TWPartner90%Source ↗

Trusval Technology Co Ltd6667.TWOPartner90%Source ↗

Vendors1

Swiss Properties Invest A/SSWISS.COVendor100%Source ↗

Supply chain

Vendors → AIMD ↔ Partners → Customers · click any node to drill

5 mentions in 10-K0 from corporate websites0 from news dispatches

Updated 2026-07-04

Peer comparison

Peer comparison8 peers · vs AIMD · multiples and returns

KLAR—

KLAR.ST

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

BNTX—

Biontech SE

$92,25

23,3B USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

EXEL—

Exelixis Inc

$55,06

14,7B USD

P/E

19,5x

— vs self

Div yield

—

— vs self

ROE

40,4 %

+235,8 vs self

MDGL—

Madrigal Pharmaceuticals Inc

$482,00

11,0B USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

-47,8 %

+147,5 vs self

INSM—

Insmed Inc

$107,46

23,0B USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

-160,2 %

+35,1 vs self

VCYT—

Veracyte Inc

$45,30

3,6B USD

P/E

55,5x

— vs self

Div yield

—

— vs self

ROE

5,1 %

+200,4 vs self

MDXG—

Mimedx Group Inc

$4,27

636,0M USD

P/E

11,1x

— vs self

Div yield

—

— vs self

ROE

18,9 %

+214,3 vs self

AVIR—

Atea Pharmaceuticals Inc

$4,61

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

-57,5 %

+137,8 vs self

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

— missing data

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskMedium

Filing-based flags

Net cash is negative after subtracting total debt.

Benchmarks vs cohort

Op Margin-11 268,0 %Bottom quartile

Net Margin-11 896,8 %Bottom quartile

ROE-195,3 %Bottom quartile

Capex / Rev-27,8 %Bottom quartile

D/E1,45Bottom quartile

Cash Conv0,31Bottom quartile

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net acquired 5 994 sh11 grants9 insiders

lee ting-chuanDirector · RSU → Common StockAcquired 570 000grant · 2026-04-15
TSAI CHUN-JUNGDirector · RSU → Common StockAcquired 330 000grant · 2026-04-15
TSAI CHUN-JUNGDirector · RSU → Common StockDisposed 330 000conversion · 2026-04-15
tsai chun-hsienDirector, CEO, PRESIDENT, CHAIRMAN · RSU → Common StockAcquired 300 000grant · 2026-04-15
tsai chun-hsienDirector, CEO, PRESIDENT, CHAIRMAN · RSU → Common StockDisposed 300 000conversion · 2026-04-15
lee ting-chuanDirector · RSU → Common StockDisposed 570 000conversion · 2026-04-15
ASE Test, Inc.10% owner · 6% Convertible Note due 2027 (previously due 2025) → Common Stock, par value $0.01Acquired 5 994 @ $22,50purchase · 2026-04-12
Lee Hsin-Liang ChristopherCFO · RSU → Common StockAcquired 20 000grant · 2025-11-25
chiang yao-chungDirector · RSU → Common StockAcquired 50 000grant · 2025-11-25
chiang yao-chungDirector · RSU → Common StockDisposed 50 000conversion · 2025-11-25
tsai chun-hsienDirector, CEO, PRESIDENT, CHAIRMAN · RSU → Common StockAcquired 80 000grant · 2025-11-25
tsai chun-hsienDirector, CEO, PRESIDENT, CHAIRMAN · RSU → Common StockDisposed 80 000conversion · 2025-11-25
lee ting-chuanDirector · RSU → Common StockAcquired 80 000grant · 2025-11-25
lee ting-chuanDirector · RSU → Common StockDisposed 80 000conversion · 2025-11-25
chang wen-hanDirector · RSU → Common StockAcquired 50 000grant · 2025-11-25
chang wen-hanDirector · RSU → Common StockDisposed 50 000conversion · 2025-11-25
tsai chung-yiDirector · RSU → Common StockAcquired 50 000grant · 2025-11-25
tsai chung-yiDirector · RSU → Common StockDisposed 50 000conversion · 2025-11-25
WEI PAO-SHENGDirector · RSU → Common StockDisposed 50 000conversion · 2025-11-25
WEI PAO-SHENGDirector · RSU → Common StockAcquired 50 000grant · 2025-11-25
TSAI CHUN-JUNGDirector · RSU → Common StockDisposed 80 000conversion · 2025-11-25
Lee Hsin-Liang ChristopherCFO · RSU → Common StockDisposed 20 000conversion · 2025-11-25
TSAI CHUN-JUNGDirector · RSU → Common StockAcquired 80 000grant · 2025-11-25

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Return On Equity
net_income / total_equity
Price To Book
market_price / (adjusted_book_value / shares_outstanding_diluted)
Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Market Price
input from market-data provider (delayed close or quote-shim mid)
Market Cap
market_price * shares_outstanding_diluted
Ev To Revenue
enterprise_value / revenue

Source documents

Ainos Inc Market data — financials · 2026-05-27
Ainos Inc Market data — analyst estimates · 2026-05-27

Ownership & reference

Top holders

Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$0M
Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$0M
BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$0M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M

Insider activity

Net selling9 buys · 9 sellsnet -$469K9 insiders · last 365d

chiang yao-chungDirector · Common StockBought 3 500 @ $2,05$7K · 2026-06-05
chiang yao-chungDirector · Common StockBought 2 000 @ $2,13$4K · 2026-06-03
chiang yao-chungDirector · Common StockBought 250 @ $2,30$575 · 2026-05-28
chiang yao-chungDirector · Common StockBought 2 000 @ $2,00$4K · 2026-05-27
TSAI CHUN-JUNGDirector · Common StockSold 27 718 @ $1,87$52K · 2026-05-26
lee ting-chuanDirector · Common StockSold 109 988 @ $1,90$209K · 2026-05-26
Taiwan Carbon Nano Technology Corp10% owner · Common StockSold 41 000 @ $2,36$97K · 2026-05-26
lee ting-chuanDirector · Common StockSold 9 302 @ $1,57$15K · 2026-05-22
TSAI CHUN-JUNGDirector · Common StockSold 1 082 @ $1,55$2K · 2026-05-22
lee ting-chuanDirector · Common StockSold 9 000 @ $1,56$14K · 2026-05-21
chiang yao-chungDirector · Common StockBought 2 200 @ $1,68$4K · 2026-05-19
chiang yao-chungDirector · Common StockBought 500 @ $1,65$825 · 2026-05-18
chiang yao-chungDirector · Common StockBought 129 @ $1,70$219 · 2026-05-05
chiang yao-chungDirector · Common StockBought 200 @ $1,68$336 · 2026-04-30
chiang yao-chungDirector · Common StockBought 100 @ $1,75$175 · 2026-04-29
tsai chun-hsienDirector, CEO, PRESIDENT, CHAIRMAN · Common StockOther 300 000 @ $1,61$483K · 2026-04-15
lee ting-chuanDirector · Common StockOther 570 000 @ $1,61$918K · 2026-04-15
TSAI CHUN-JUNGDirector · Common StockOther 330 000 @ $1,61$531K · 2026-04-15
Taiwan Carbon Nano Technology Corp10% owner · Common StockSold 46 000 @ $2,17$100K · 2026-01-28
Taiwan Carbon Nano Technology Corp10% owner · Common StockSold 431 @ $1,86$802 · 2026-01-09
Taiwan Carbon Nano Technology Corp10% owner · Common StockSold 850 @ $1,80$2K · 2026-01-08
lee ting-chuanDirector · Common StockOther 80 000 @ $2,10$168K · 2025-11-25
chang wen-hanDirector · Common StockOther 50 000 @ $2,10$105K · 2025-11-25
tsai chung-yiDirector · Common StockOther 50 000 @ $2,10$105K · 2025-11-25
WEI PAO-SHENGDirector · Common StockOther 50 000 @ $2,10$105K · 2025-11-25

Short positioning

14.2Kshares short+0.5% vs prior

1days to cover

32.3%short of daily vol

67fails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

AIMD.OCanonical

NASDAQ · USD

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskMedium

Net cash is negative after subtracting total debt.

Relationship graph

This companySectorCustomersPartnersVendors

Evidence & claims

From filings & derived data

Operating income (YoY) (2025-12-31 vs 2024-12-31): -1.1%Derived (calculated)
Debt-to-equity (FY 2025-12-31): 1.76xDerived (calculated)
Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 20.5%Derived (calculated)
Gross margin (FY 2025-12-31): 82.9%Derived (calculated)
Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -51.3%Derived (calculated)
Capex (YoY) (2025-12-31 vs 2024-12-31): 62.0%Derived (calculated)
Total assets (YoY) (2025-12-31 vs 2024-12-31): -27.6%Derived (calculated)
Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -89.3%Derived (calculated)
Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 0.0%Derived (calculated)
Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): -59.6%Derived (calculated)
EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 55.8%Derived (calculated)
Gross profit (YoY) (2025-12-31 vs 2024-12-31): 422.9%Derived (calculated)
EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 55.8%Derived (calculated)
Net income (YoY) (2025-12-31 vs 2024-12-31): 0.6%Derived (calculated)
Net margin (FY 2025-12-31): -11,897.0%Derived (calculated)
Current ratio (FY 2025-12-31): 1.06xDerived (calculated)
Revenue (YoY) (2025-12-31 vs 2024-12-31): 499.0%Derived (calculated)
R&D expense (YoY) (2025-12-31 vs 2024-12-31): -7.9%Derived (calculated)
Return on assets (FY 2025-12-31): -70.8%Derived (calculated)
Return on equity (FY 2025-12-31): -195.3%Derived (calculated)
Total assets (annual): USD 20.87MSEC XBRL filing
Net income (annual): USD -14.77MSEC XBRL filing
Pre-tax income (annual): USD -14.77MSEC XBRL filing
Cash & equivalents (annual): USD 417.35KSEC XBRL filing

Showing 24 of 60 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date

2026-06-05 00:00 UTCINSIDER2 insider transactions — 2026-06

2026-06-05INSIDERchiang yao-chung bought 3.5k sh — Director ~$7k

2026-06-03INSIDERchiang yao-chung bought 2.0k sh — Director ~$4k

2026-05-28 00:00 UTCINSIDER11 insider transactions — 2026-05 · net sell $379k

2026-05-28INSIDERchiang yao-chung bought 250 sh — Director ~$1k

2026-05-27INSIDERchiang yao-chung bought 2.0k sh — Director ~$4k

2026-05-26INSIDERTSAI CHUN-JUNG sold 27.7k sh — Director ~$52k

2026-05-26INSIDERlee ting-chuan sold 110.0k sh — Director ~$209k

2026-05-26INSIDERTaiwan Carbon Nano Technology Corp sold 41.0k sh — 10% owner ~$97k

2026-05-22INSIDERlee ting-chuan sold 9.3k sh — Director ~$15k

2026-05-22INSIDERTSAI CHUN-JUNG sold 1.1k sh — Director ~$2k

2026-05-21INSIDERlee ting-chuan sold 9.0k sh — Director ~$14k

2026-05-19INSIDERchiang yao-chung bought 2.2k sh — Director ~$4k

2026-05-18INSIDERchiang yao-chung bought 500 sh — Director ~$1k

2026-05-13FILING10-Q filing →

2026-05-13FILING8-K filing →

2026-05-05INSIDERchiang yao-chung bought 129 sh — Director ~$0k

2026-04-30 00:00 UTCINSIDER12 insider transactions — 2026-04 · net buy $1.9M 7 derivative

2026-04-30INSIDERchiang yao-chung bought 200 sh — Director ~$0k

2026-04-29INSIDERchiang yao-chung bought 100 sh — Director ~$0k

2026-04-15INSIDERtsai chun-hsien transacted 300.0k sh — Director, CEO, PRESIDENT, CHAIRMAN ~$483k

2026-04-15INSIDERlee ting-chuan transacted 570.0k sh — Director ~$918k

2026-04-15INSIDERTSAI CHUN-JUNG transacted 330.0k sh — Director ~$531k

2026-04-15INSIDERlee ting-chuan acquired 570.0k sh RSU — Director

2026-04-15INSIDERtsai chun-hsien acquired 300.0k sh RSU — Director, CEO, PRESIDENT, CHAIRMAN

2026-04-15INSIDERtsai chun-hsien disposed of 300.0k sh RSU — Director, CEO, PRESIDENT, CHAIRMAN

2026-04-15INSIDERTSAI CHUN-JUNG disposed of 330.0k sh RSU — Director

2026-04-15INSIDERlee ting-chuan disposed of 570.0k sh RSU — Director

2026-04-15INSIDERTSAI CHUN-JUNG acquired 330.0k sh RSU — Director

2026-04-12INSIDERASE Test, Inc. acquired 6.0k sh 6% Convertible Note due 2027 (previously due 2025) — 10% owner

2026-03-30FILING10-K filing →

2026-03-30FILING8-K filing →

2026-01-28 00:00 UTCINSIDER3 insider transactions — 2026-01 · net sell $102k

2026-01-28INSIDERTaiwan Carbon Nano Technology Corp sold 46.0k sh — 10% owner ~$100k

2026-01-09INSIDERTaiwan Carbon Nano Technology Corp sold 431 sh — 10% owner ~$1k

2026-01-08INSIDERTaiwan Carbon Nano Technology Corp sold 850 sh — 10% owner ~$2k

2026-01-06FILING8-K filing →

2026-01-05FILING8-K filing →

2025-12-31FILING8-K filing →

Showing the 40 most recent of 58 entries.

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread